[go: up one dir, main page]

WO2003084986A3 - Nouveaux polypeptides modifies impliques dans le metabolisme cellulaire - Google Patents

Nouveaux polypeptides modifies impliques dans le metabolisme cellulaire Download PDF

Info

Publication number
WO2003084986A3
WO2003084986A3 PCT/CA2003/000464 CA0300464W WO03084986A3 WO 2003084986 A3 WO2003084986 A3 WO 2003084986A3 CA 0300464 W CA0300464 W CA 0300464W WO 03084986 A3 WO03084986 A3 WO 03084986A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellular metabolism
purified polypeptides
polypeptides involved
novel purified
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/000464
Other languages
English (en)
Other versions
WO2003084986A2 (fr
Inventor
Aled Edwards
Akil Dharamsi
Masoud Vedadi
Megan Domagala
Dhushy Kanagarajah
Hui Ouyang
Simon Houston
Donald Awrey
Bryan Beattie
Kathleen Nethery
Kamran Mansoury
Kristina Buzadzija
Ivy Ng
Merry-Lynn Mcdonald
Dawn Richards
Rosanne Thalakada
Cristina Virag
Muhammad Zahoor Alam
Veronica Canadien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinium Pharmaceuticals Inc
Original Assignee
Affinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharmaceuticals Inc filed Critical Affinium Pharmaceuticals Inc
Priority to AU2003213935A priority Critical patent/AU2003213935A1/en
Publication of WO2003084986A2 publication Critical patent/WO2003084986A2/fr
Publication of WO2003084986A3 publication Critical patent/WO2003084986A3/fr
Priority to US10/958,216 priority patent/US20050181388A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/04—Processes using organic exchangers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8804—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 automated systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des cibles polypeptides pour des bactéries pathogènes. L'invention concerne également des caractéristiques biochimiques et biophysiques desdits polypeptides.
PCT/CA2003/000464 2002-04-02 2003-04-04 Nouveaux polypeptides modifies impliques dans le metabolisme cellulaire Ceased WO2003084986A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003213935A AU2003213935A1 (en) 2002-04-04 2003-04-04 Novel purified polypeptides involved in cellular metabolism
US10/958,216 US20050181388A1 (en) 2002-04-02 2004-10-04 Novel purified polypeptides from bacteria

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US36981702P 2002-04-04 2002-04-04
US37010202P 2002-04-04 2002-04-04
US60/370,102 2002-04-04
US60/369,817 2002-04-04
US37079202P 2002-04-08 2002-04-08
US37077802P 2002-04-08 2002-04-08
US37085902P 2002-04-08 2002-04-08
US37082002P 2002-04-08 2002-04-08
US60/370,778 2002-04-08
US60/370,820 2002-04-08
US60/370,859 2002-04-08
US60/370,792 2002-04-08
US37114002P 2002-04-09 2002-04-09
US60/371,140 2002-04-09
US38601802P 2002-06-05 2002-06-05
US60/386,018 2002-06-05
US38643002P 2002-06-06 2002-06-06
US60/386,430 2002-06-06
US43684202P 2002-12-27 2002-12-27
US60/436,842 2002-12-27
US43698702P 2002-12-30 2002-12-30
US60/436,987 2002-12-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/958,216 Continuation-In-Part US20050181388A1 (en) 2002-04-02 2004-10-04 Novel purified polypeptides from bacteria

Publications (2)

Publication Number Publication Date
WO2003084986A2 WO2003084986A2 (fr) 2003-10-16
WO2003084986A3 true WO2003084986A3 (fr) 2004-02-19

Family

ID=28795495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000464 Ceased WO2003084986A2 (fr) 2002-04-02 2003-04-04 Nouveaux polypeptides modifies impliques dans le metabolisme cellulaire

Country Status (2)

Country Link
AU (1) AU2003213935A1 (fr)
WO (1) WO2003084986A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010940A1 (fr) * 2004-07-30 2006-02-02 Astrazeneca Ab Procede d'essai de synthetase fad
KR102080886B1 (ko) * 2019-05-21 2020-02-24 씨제이제일제당 주식회사 부반응성이 낮은 리불로스-인산 3-에피머화 효소의 모티프 및 이를 포함하는 효소

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786519A2 (fr) * 1996-01-05 1997-07-30 Human Genome Sciences, Inc. Polynucléotides et séquences de Staphylococcus aureus
US6037123A (en) * 1995-09-15 2000-03-14 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
WO2001077309A2 (fr) * 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Cristallisation et determination de la structure de $i(staphylococcus aureus) thioredoxine reductase
WO2002094868A2 (fr) * 2001-03-27 2002-11-28 Chiron Srl. Proteines et acides nucleiques de staphylococcus aureus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037123A (en) * 1995-09-15 2000-03-14 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
EP0786519A2 (fr) * 1996-01-05 1997-07-30 Human Genome Sciences, Inc. Polynucléotides et séquences de Staphylococcus aureus
WO2001077309A2 (fr) * 2000-04-06 2001-10-18 Pharmacia & Upjohn Company Cristallisation et determination de la structure de $i(staphylococcus aureus) thioredoxine reductase
WO2002094868A2 (fr) * 2001-03-27 2002-11-28 Chiron Srl. Proteines et acides nucleiques de staphylococcus aureus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI, Hinxton, UK; 1 June 2001 (2001-06-01), KURODA ET AL.: "CfxE protein (Ribulose-5-phosphate 3-epimerase homologue).", XP002252125, Database accession no. Q99UP6 *
DATABASE EMPAT [online] EBI, Hinxton, UK; 20 February 2003 (2003-02-20), MASIGNANI V.C.: ""Staphylococcus aureus proteins and nucleic acids"", XP002252124, Database accession no. AX617991 *
KURODA M ET AL: "Whole genome sequencing of meticillin-resistant Staphylococcus aureus", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 357, no. 9264, 21 April 2001 (2001-04-21), pages 1225 - 1240, XP004246103, ISSN: 0140-6736 *
LYNGSTADAAS^ADEPARTMENT OF CELL BIOLOGY INSTITUTE FOR CANCER RESEARCH MONTEBELLO N-0310 OSLO NORWAY A ET AL: "Impaired growth of an Escherichia coli rpe mutant lacking ribulose-5-phosphate epimerase activity", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1381, no. 3, 24 August 1998 (1998-08-24), pages 319 - 330, XP004276177, ISSN: 0304-4165 *

Also Published As

Publication number Publication date
AU2003213935A8 (en) 2003-10-20
AU2003213935A1 (en) 2003-10-20
WO2003084986A2 (fr) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2004041854A3 (fr) Nouveaux polypeptides bacteriens essentiels
WO2003087353A3 (fr) Nouveaux polypeptides purifies impliques dans la biogenese membranaire
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
WO2003044185A3 (fr) Nouveaux polypeptides purifies iimpliques dans un metabolisme general
WO2007093848A3 (fr) Nouveaux polypeptides purifiés issus de helicobacter pylori
WO2003084986A3 (fr) Nouveaux polypeptides modifies impliques dans le metabolisme cellulaire
WO2003083099A3 (fr) Nouveaux polypeptides purifies impliques dans la synthese et la modification des proteines
WO2003102190A3 (fr) Nouveaux polypeptides purifies responsables de la viabilite bacterienne
WO2004044189A3 (fr) Nouveaux polypeptides purifies jouant un role dans le metabolisme
WO2003025006A3 (fr) Nouveaux polypeptides purifies impliques dans le metabolisme des cofacteurs
WO2003087145A3 (fr) Nouveaux polypeptides purifies impliques dans la detection de densite cellulaire
WO2003027139A3 (fr) Nouveaux polypeptides purifiees impliques dans la biosynthese membranaire
WO2003045986A3 (fr) Nouveaux polypeptides purifies impliques dans le metabolisme general
WO2003087354A3 (fr) Nouveaux polypeptides purifies impliques dans le transport et le metabolisme nucleotidiques
WO2003025004A3 (fr) Polypeptides purifies intervenant dans le traitement d'acides nucleiques
WO2003025008A3 (fr) Nouveaux polypeptides purifies impliques dans le traitement de proteines
WO2004058809A3 (fr) Nouveaux polypeptides bacteriens essentiels
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes
WO2003025007A3 (fr) Nouveaux polypeptides purifies impliques dans la biosynthese membranaire
WO2003084987A3 (fr) Nouveaux polypeptides purifies intervenant dans la synthese et la transformation de l'acide nucleique
WO2003045985A3 (fr) Nouveaux polypeptides purifies impliques dans le metabolisme coenzymatique et glucidique
WO2003025005A3 (fr) Nouveaux polypeptides purifies impliques dans le traitement des proteines
WO2004081206A3 (fr) Nouveaux polypeptides codes par des genes bacteriens essentiels
WO2003085103A3 (fr) Nouveaux polypeptides purifies impliques dans l'hydrolyse de nucleotides
WO2003035858A3 (fr) Nouveaux polypeptides purifies impliques dans le traitement des acides nucleiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP